Results 11 to 20 of about 6,619 (182)

Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD) [PDF]

open access: yesTherapeutic Advances in Endocrinology and Metabolism, 2023
The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium
Ploutarchos Tzoulis   +4 more
doaj   +5 more sources

Tolvaptan

open access: yesSouth Asian Journal of Cancer, 2014
Abstract Hyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance.
Bharath Rangarajan   +3 more
openaire   +4 more sources

Tolvaptan induces body fluid loss and subsequent water conservation in normal rats

open access: yesJournal of Pharmacological Sciences, 2022
We have recently reported that the urea osmolyte-associated water conservation system is activated in fluid loss models such as high salt-induced natriuresis, renal injury-induced impaired renal concentrating ability, or skin barrier dysfunction-induced ...
Satoshi Kidoguchi   +6 more
doaj   +3 more sources

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction

open access: yesInternational Journal of Cardiology: Heart & Vasculature, 2018
Background: Tolvaptan is a vasopressin type 2 receptor antagonist used in heart failure (HF) with refractory diuretic resistance. However, since tolvaptan is also ineffective in some HF patients with reduced ejection fraction (HFrEF), the identification ...
Shinichi Nonin   +9 more
doaj   +2 more sources

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia [PDF]

open access: yesBMC Gastroenterology, 2018
Background Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients.
Shuzhen Wang   +8 more
doaj   +3 more sources

Real‐World Effectiveness of Tolvaptan for Hyponatremia in Cirrhosis Across Global Regions: A Target Trial Emulation [PDF]

open access: yesJGH Open
Background Tolvaptan promotes electrolyte‐free water excretion and is widely used in Asia for ascites, but in Western countries its use is limited to hyponatremia because of hepatotoxicity concerns. Methods We performed a retrospective cohort study using
Kazuya Okushin   +5 more
doaj   +2 more sources

Renal ultrasonography predicts worsening renal function in patients with heart failure under tolvaptan administration

open access: yesESC Heart Failure
Aims Renal dysfunction in patients with chronic heart failure predicts a poor prognosis. Tolvaptan has a diuretic effect in patients with chronic kidney disease and heart failure without adverse effects on renal function.
Nobukiyo Tanaka   +14 more
doaj   +2 more sources

Trajectories of Kidney Function in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan [PDF]

open access: yesMedicina
Background and Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease, and the only approved pharmacological therapy shown to slow disease progression is tolvaptan.
Zofia Jankowska, Mariusz Niemczyk
doaj   +2 more sources

Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre-Specified Secondary Analysis of the TVFR Trial. [PDF]

open access: yesClin Endocrinol (Oxf)
ABSTRACT Objective Hyponatraemia is a common electrolyte disorder often driven by excess arginine vasopressin (AVP). Copeptin is a stable surrogate marker co‐secreted with AVP. It is unclear whether treatment of hyponatraemia with tolvaptan, an AVP‐V2 receptor antagonist, impacts copeptin.
Warren AM   +4 more
europepmc   +2 more sources

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use

open access: yesPLoS ONE, 2022
Polycystic liver disease (PLD) is a common extrarenal complication of autosomal dominant polycystic kidney disease (ADPKD), which causes compression-related syndrome and ultimately leads to liver dysfunction.
Hiroki Mizuno   +8 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy